Efficacy of moxonidine in the treatment of hypertension in obese, noncontrolled hypertensive patients

This publication has 35 references indexed in Scilit:

• Effects of Moxonidine vs. Metoprolol on Blood Pressure and Metabolic Control in Hypertensive Subjects with Type 2 Diabetes
  Experimental and Clinical Endocrinology & Diabetes, 2004
• The Role of I₁‐Imidazoline Receptors and a₂‐Adrenergic Receptors in the Modulation of Glucose and Lipid Metabolism in the SHROB Model of Metabolic Syndrome X
  Annals of the New York Academy of Sciences, 2003
• Cardiac Effects of Moxonidine in Spontaneously Hypertensive Obese Rats
  Annals of the New York Academy of Sciences, 2003
• The Role of I1-Imidazoline and α2-Adrenergic Receptors in the Modulation of Glucose Metabolism in the Spontaneously Hypertensive Obese Rat Model of Metabolic Syndrome X
  The Journal of Pharmacology and Experimental Therapeutics, 2003
• Insulin Resistance and Diabetes in the Context of Treatment of Hypertension
  Blood Pressure, 1998
• Therapy of Hypertension and Metabolic Syndrome: Today's Standard and Tomorrow's Perspectives
  Blood Pressure, 1998
• Antihypertensive Agent Moxonidine Enhances Muscle Glucose Transport in Insulin-Resistant Rats
  Hypertension, 1997
• The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure
  Archives of internal medicine (1960), 1997
• Excess catecholamines and the metabolic syndrome: Should central imidazoline receptors be a therapeutic target?
  Medical Hypotheses, 1995
• Additive effects of obesity, hypertension, and type 2 diabetes on insulin resistance.
  Hypertension, 1994